Skip to main content
Novartis AG logo

Novartis AG — Investor Relations & Filings

Ticker · NOVN ISIN · CH0038459415 LEI · 5493007HIVTX6SY6XD66 SW Manufacturing
Open in API
Filings indexed 1,070 across all filing types
Latest filing 2018-06-19 Director's Dealing
Country CH Switzerland
Listing SW NOVN

About Novartis AG

https://www.novartis.com/

Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2018-06-19 English
PRIMARY DOCUMENT
Director's Dealing
2018-06-15 English
FORM 6-K
Regulatory Filings
2018-06-01 English
FORM 6-K
Regulatory Filings
2018-06-01 English
Novartis completes sale of stake in consumer healthcare joint venture to GSK for USD13.0 billion
M&A Activity Classification · 99% confidence The document is a press release from Novartis AG, dated June 1, 2018, announcing the completion of the divestment of its stake in a consumer healthcare joint venture to GSK for USD 13.0 billion. This is a specific corporate action announcement regarding a major transaction (divestment/sale). It is not a comprehensive annual report (10-K), a quarterly report (IR), an earnings release (ER), or a management discussion (MDA). It is a specific corporate event announcement. Since there is no specific category for 'Divestment Announcement' or 'Major Transaction Announcement', the most appropriate general category for a significant, non-standard corporate event announcement that is not a standard financial report or management change is 'Regulatory Filings' (RNS), which serves as a broad category for regulatory/corporate news releases that don't fit elsewhere, or potentially 'Capital/Financing Update' (CAP) if viewed as a capital structure change, but RNS is safer for general press releases of this nature. Given the context of major corporate news dissemination via Nasdaq Corporate Solutions, RNS is the best fit among the provided options for a press release detailing a completed transaction.
2018-06-01 English
Novartis receives positive CHMP opinion for Aimovig® (erenumab) for the prevention of migraine
Regulatory Filings Classification · 95% confidence The document is a press release from Novartis announcing that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval for their drug Aimovig® (erenumab). This type of announcement, detailing regulatory milestones (like a positive opinion or FDA approval) and providing context on the drug's efficacy and market status, is characteristic of a corporate news release regarding product development or regulatory progress. It is not a comprehensive financial report (10-K, IR), a management discussion (MDA), or a transcript (CT). Since it is an announcement of a significant event (regulatory decision) that is not explicitly covered by other codes like DIV, CAP, or MANG, and it functions as general corporate news, it fits best under the general Regulatory Filings (RNS) category, which serves as a fallback for important, non-standard announcements. Given the length and content, it is not a short 'Report Publication Announcement' (RPA).
2018-06-01 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.